Greg Davis, PhD, has nearly 35 years’ experience in drug development in biotech and pharma. Dr. Davis is our Vice President, Product Development.

Dr. Davis has served as Chairman of the Board of Inotiv, a publicly-traded clinical research organization, since June 2017. He served as Vice President of CMC, Regulatory and Quality at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, from May 2014 to December 2015. The company was sold to Novo Nordisk in October 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. When he retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principal Fellow in Global Regulatory Affairs. Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his PhD in Analytical Chemistry from Purdue University.